Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency

J Infect Dis. 2019 Oct 22;220(11):1750-1760. doi: 10.1093/infdis/jiz313.

Abstract

Background: Hemoglobin (Hb) data are limited in Southeast Asian glucose-6-phosphate dehydrogenase (G6PD) deficient (G6PD-) patients treated weekly with the World Health Organization-recommended primaquine regimen (ie, 0.75 mg/kg/week for 8 weeks [PQ 0.75]).

Methods: We treated Cambodians who had acute Plasmodium vivax infection with PQ0.75 and a 3-day course of dihydroartemisinin/piperaquine and determined the Hb level, reticulocyte count, G6PD genotype, and Hb type.

Results: Seventy-five patients (male sex, 63) aged 5-63 years (median, 24 years) were enrolled. Eighteen were G6PD deficient (including 17 with G6PD Viangchan) and 57 were not G6PD deficient; 26 had HbE (of whom 25 were heterozygous), and 6 had α-/β-thalassemia. Mean Hb concentrations at baseline (ie, day 0) were similar between G6PD deficient and G6PD normal patients (12.9 g/dL [range, 9‒16.3 g/dL] and 13.26 g/dL [range, 9.6‒16 g/dL], respectively; P = .46). G6PD deficiency (P = <.001), higher Hb concentration at baseline (P = <.001), higher parasitemia level at baseline (P = .02), and thalassemia (P = .027) influenced the initial decrease in Hb level, calculated as the nadir level minus the baseline level (range, -5.8-0 g/dL; mean, -1.88 g/dL). By day 14, the mean difference from the day 7 level (calculated as the day 14 level minus the day 7 level) was 0.03 g/dL (range, -0.25‒0.32 g/dL). Reticulocyte counts decreased from days 1 to 3, peaking on day 7 (in the G6PD normal group) and day 14 (in the G6PD deficient group); reticulocytemia at baseline (P = .001), G6PD deficiency (P = <.001), and female sex (P = .034) correlated with higher counts. One symptomatic, G6PD-deficient, anemic male patient was transfused on day 4.

Conclusions: The first PQ0.75 exposure was associated with the greatest decrease in Hb level and 1 blood transfusion, followed by clinically insignificant decreases in Hb levels. PQ0.75 requires monitoring during the week after treatment. Safer antirelapse regimens are needed in Southeast Asia.

Clinical trials registration: ACTRN12613000003774.

Keywords: Cambodia; Primaquine; glucose-6-phosphate dehydrogenase deficiency; hemoglobin E; malaria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antimalarials / administration & dosage*
  • Antimalarials / adverse effects
  • Asian People
  • Chemoprevention / adverse effects
  • Chemoprevention / methods*
  • Child
  • Child, Preschool
  • Female
  • Glucosephosphate Dehydrogenase
  • Glucosephosphate Dehydrogenase Deficiency*
  • Hemoglobins / analysis
  • Hemolysis*
  • Humans
  • Malaria, Vivax / drug therapy*
  • Male
  • Middle Aged
  • Primaquine / administration & dosage*
  • Primaquine / adverse effects
  • Reticulocyte Count
  • Secondary Prevention / methods*
  • Young Adult

Substances

  • Antimalarials
  • Hemoglobins
  • G6PD protein, human
  • Glucosephosphate Dehydrogenase
  • Primaquine

Associated data

  • ANZCTR/ACTRN12613000003774